| Dr Patricia Adedotun Ajayi-fox, MD | |
|
619 19th St S, Birmingham, AL 35249-1900 | |
| (205) 934-4011 | |
| Not Available |
| Full Name | Dr Patricia Adedotun Ajayi-fox |
|---|---|
| Gender | Female |
| Speciality | Gastroenterology |
| Experience | 9 Years |
| Location | 619 19th St S, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790166221 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 44346 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Alabama Hospital | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cooper Green Mercy Health Services Authority An Affiliate Of Uab | 0840629473 | 49 |
| University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
"In their latest assault on President Obama's health care plans, Republicans are aiming for a vulnerable spot - the fears of seniors that their care will get worse or more costly," the Boston Globe reports on its Political Intelligence blog.
Repligen Corporation announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.
Glioblastoma is an aggressive, killer disease. While victims of this fast-moving brain tumor comprise only about 15% of all people with brain cancer, its victims rarely survive more than a few years after diagnosis.
The New York State Office for People With Developmental Disabilities' Institute for Basic Research in Developmental Disabilities has received a $1.95 million grant, for a five-year period, from the National Institute of Health's National Institute of General Medical Sciences to support IBR physician-scientist Gholson Lyon, MD, PhD, in his research on rare diseases.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
› Verified 5 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
"In their latest assault on President Obama's health care plans, Republicans are aiming for a vulnerable spot - the fears of seniors that their care will get worse or more costly," the Boston Globe reports on its Political Intelligence blog.
Repligen Corporation announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.
Glioblastoma is an aggressive, killer disease. While victims of this fast-moving brain tumor comprise only about 15% of all people with brain cancer, its victims rarely survive more than a few years after diagnosis.
The New York State Office for People With Developmental Disabilities' Institute for Basic Research in Developmental Disabilities has received a $1.95 million grant, for a five-year period, from the National Institute of Health's National Institute of General Medical Sciences to support IBR physician-scientist Gholson Lyon, MD, PhD, in his research on rare diseases.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
› Verified 5 days ago
| Entity Name | Cooper Green Mercy Health Services Authority An Affiliate Of Uab |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366073108 PECOS PAC ID: 0840629473 Enrollment ID: O20200402003238 |
News Archive
"In their latest assault on President Obama's health care plans, Republicans are aiming for a vulnerable spot - the fears of seniors that their care will get worse or more costly," the Boston Globe reports on its Political Intelligence blog.
Repligen Corporation announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.
Glioblastoma is an aggressive, killer disease. While victims of this fast-moving brain tumor comprise only about 15% of all people with brain cancer, its victims rarely survive more than a few years after diagnosis.
The New York State Office for People With Developmental Disabilities' Institute for Basic Research in Developmental Disabilities has received a $1.95 million grant, for a five-year period, from the National Institute of Health's National Institute of General Medical Sciences to support IBR physician-scientist Gholson Lyon, MD, PhD, in his research on rare diseases.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patricia Adedotun Ajayi-fox, MD Po Box 55310, Birmingham, AL 35255-5310 Ph: () - | Dr Patricia Adedotun Ajayi-fox, MD 619 19th St S, Birmingham, AL 35249-1900 Ph: (205) 934-4011 |
News Archive
"In their latest assault on President Obama's health care plans, Republicans are aiming for a vulnerable spot - the fears of seniors that their care will get worse or more costly," the Boston Globe reports on its Political Intelligence blog.
Repligen Corporation announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.
Glioblastoma is an aggressive, killer disease. While victims of this fast-moving brain tumor comprise only about 15% of all people with brain cancer, its victims rarely survive more than a few years after diagnosis.
The New York State Office for People With Developmental Disabilities' Institute for Basic Research in Developmental Disabilities has received a $1.95 million grant, for a five-year period, from the National Institute of Health's National Institute of General Medical Sciences to support IBR physician-scientist Gholson Lyon, MD, PhD, in his research on rare diseases.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
› Verified 5 days ago
Juan Mario Bernal, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3680 Grandview Pkwy Ste 200, Birmingham, AL 35243 Phone: 205-971-7500 | |
Dr. William Randolph Maddox, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 701 Princeton Ave Sw, Birmingham, AL 35211 Phone: 205-783-3000 Fax: 205-297-9411 | |
Jodie Ann Dionne, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 703 19th St S Bldg 206, Birmingham, AL 35233 Phone: 205-975-6530 | |
Dr. Karl Tullio Schroeder, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 817 Princeton Ave Sw Ste 199, Birmingham, AL 35211 Phone: 205-780-1920 Fax: 205-780-2345 | |
Dr. Deepti Bahl, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2000 6th Ave S, Birmingham, AL 35233 Phone: 205-934-9999 | |
Amitkumar Mehta, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1720 2nd Ave S # Np2540t, Birmingham, AL 35294 Phone: 205-996-8400 Fax: 205-934-1608 | |
Shana Monika Machado, D.O. Gastroenterology Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-4011 |